GlassScriptPhysician profile
Soheil Niku
NPI 1114994274
$562.43
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $71.34 · 2021: $224 · 2022: $123 · 2024: $19.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $163.84 | 2020-2021 | |
| Procept Biorobotics Corporation | $72.68 | 2022 | |
| Olympus America INC. | $71.91 | 2019-2022 | |
| Boston Scientific Corporation | $64.61 | 2019-2021 | |
| Abbvie INC. | $51.04 | 2021-2024 | |
| Janssen Biotech, INC. | $37.18 | 2019-2020 | |
| Urogen Pharma, INC. | $35.51 | 2021 | |
| Richard Wolf Medical Instruments Corp. | $25.13 | 2019 | |
| Astellas Pharma US INC | $15.65 | 2020 | |
| Myovant Sciences INC. | $13.38 | 2021 | |
| Pfizer INC. | $11.50 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.45 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soheil Niku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.